PT3209295T - Métodos de tratamento das condições oculares - Google Patents
Métodos de tratamento das condições ocularesInfo
- Publication number
- PT3209295T PT3209295T PT158523407T PT15852340T PT3209295T PT 3209295 T PT3209295 T PT 3209295T PT 158523407 T PT158523407 T PT 158523407T PT 15852340 T PT15852340 T PT 15852340T PT 3209295 T PT3209295 T PT 3209295T
- Authority
- PT
- Portugal
- Prior art keywords
- methods
- treating ocular
- ocular conditions
- conditions
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462066280P | 2014-10-20 | 2014-10-20 | |
| US201562100844P | 2015-01-07 | 2015-01-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3209295T true PT3209295T (pt) | 2021-02-05 |
Family
ID=55748136
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT158523407T PT3209295T (pt) | 2014-10-20 | 2015-10-19 | Métodos de tratamento das condições oculares |
| PT202125563T PT3848028T (pt) | 2014-10-20 | 2015-10-19 | Métodos de tratamento de estados oculares |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT202125563T PT3848028T (pt) | 2014-10-20 | 2015-10-19 | Métodos de tratamento de estados oculares |
Country Status (21)
| Country | Link |
|---|---|
| US (14) | US9504645B2 (enExample) |
| EP (3) | EP3209295B2 (enExample) |
| JP (3) | JP6873906B2 (enExample) |
| KR (2) | KR102601505B1 (enExample) |
| CN (3) | CN107106542B (enExample) |
| AU (2) | AU2015336216B2 (enExample) |
| BR (2) | BR122022025737B1 (enExample) |
| CA (1) | CA2965129C (enExample) |
| DK (2) | DK3209295T4 (enExample) |
| EA (1) | EA035335B1 (enExample) |
| ES (2) | ES2848977T5 (enExample) |
| FI (1) | FI3848028T3 (enExample) |
| IL (3) | IL293188B2 (enExample) |
| MX (2) | MX392383B (enExample) |
| MY (1) | MY186870A (enExample) |
| PH (1) | PH12017500602A1 (enExample) |
| PL (1) | PL3848028T3 (enExample) |
| PT (2) | PT3209295T (enExample) |
| SG (2) | SG10202011669PA (enExample) |
| WO (1) | WO2016064759A1 (enExample) |
| ZA (1) | ZA201703467B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107106542B (zh) | 2014-10-20 | 2020-05-08 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
| NZ746468A (en) * | 2016-04-07 | 2023-06-30 | Oyster Point Pharma Inc | Methods of treating ocular conditions |
| WO2020014217A1 (en) * | 2018-07-10 | 2020-01-16 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| EP3820443A1 (en) | 2018-07-10 | 2021-05-19 | Oyster Point Pharma, Inc. | Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions |
| EP4142734B1 (en) | 2020-04-28 | 2025-08-20 | Oyster Point Pharma, Inc. | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
| JP2024517459A (ja) * | 2021-05-07 | 2024-04-22 | オイスター ポイント ファーマ インコーポレイテッド | ベクター及びニコチン作動薬の併用療法 |
| WO2025037323A1 (en) * | 2023-08-12 | 2025-02-20 | Pavan Kumar Kothapuvari | Pharmaceutical compositions for treatment of dry eye disease and associated disorders |
| DE102023208057A1 (de) * | 2023-08-23 | 2025-02-27 | Ursapharm Arzneimittel Gmbh | Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277855B1 (en) | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| US20030008892A1 (en) | 2001-07-09 | 2003-01-09 | Pfizer Inc. | Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| IL161326A0 (en) | 2001-11-29 | 2004-09-27 | Pfizer Prod Inc | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| AU2003269413A1 (en) * | 2002-11-01 | 2004-05-25 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| US20060270592A1 (en) * | 2004-03-19 | 2006-11-30 | Ophthalmic Research Associates, Inc. | Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
| EP1802276A1 (en) * | 2004-10-15 | 2007-07-04 | Pfizer Products Inc. | Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline |
| CA2578176C (en) * | 2004-11-09 | 2013-09-24 | Novagali Pharma Sa | Ophthalmic emulsions containing an immunosuppressive agent |
| US20090023819A1 (en) * | 2005-03-22 | 2009-01-22 | Anders Axelsson | Use of an Artificial Sweetener to Enhance Absorption of Nicotine |
| US20110086086A1 (en) | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
| JP5276982B2 (ja) | 2005-08-26 | 2013-08-28 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | オキシトシンの投与による頭痛の処置のための方法 |
| JP5505760B2 (ja) | 2005-09-27 | 2014-05-28 | ティッシュテク・インコーポレーテッド | 羊膜調製物及び精製組成物及びその使用方法 |
| TWI405763B (zh) | 2006-11-02 | 2013-08-21 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
| US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| DK2114970T3 (da) * | 2007-02-02 | 2011-09-19 | Pfizer Prod Inc | Tricykliske forbindelser og deres anvendelse som glucocorticoidreceptormodulatorer |
| EP1977746B8 (en) * | 2007-04-02 | 2014-09-24 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
| US20090093446A1 (en) | 2007-10-05 | 2009-04-09 | Winston Laboratories, Inc. | Method for alleviating keratoconjunctivitis sicca |
| CL2008003507A1 (es) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| US20090215787A1 (en) | 2008-02-22 | 2009-08-27 | Mai De Ltd. | Preparations of new polymorphic forms of varenicline tartrate |
| US20110071180A1 (en) | 2008-03-05 | 2011-03-24 | Targacept, Inc. | Sub-type selective amides of diazabicycloalkanes |
| WO2010028011A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| JP2012502039A (ja) | 2008-09-05 | 2012-01-26 | ターガセプト，インコーポレイテッド | ジアザビシクロオクタンのアミド及びその用途 |
| IL266097B (en) | 2008-12-01 | 2022-07-01 | Oyster Point Pharma Inc | Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine |
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| US8821457B2 (en) * | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
| US20140170157A1 (en) * | 2011-06-15 | 2014-06-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
| CN103619354A (zh) * | 2011-06-30 | 2014-03-05 | 东丽株式会社 | 止痒剂 |
| IN2014CN03647A (enExample) * | 2011-10-20 | 2015-10-09 | Novartis Ag | |
| US20140357971A1 (en) * | 2011-11-30 | 2014-12-04 | Diagnostear Ltd. | Dry eye diagnostic |
| ES2426517B1 (es) * | 2012-04-20 | 2014-05-14 | Genetracer Biotech S.L | Método para predecir la seguridad de un tratamiento farmacológico |
| EP2968368B1 (en) | 2013-03-15 | 2017-08-09 | Glia LLC | Cranial delivery of pharmaceuticals |
| CN108744272A (zh) | 2013-04-19 | 2018-11-06 | 奥库利维公司 | 鼻刺激装置和方法 |
| CN107106542B (zh) | 2014-10-20 | 2020-05-08 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
| NZ746468A (en) | 2016-04-07 | 2023-06-30 | Oyster Point Pharma Inc | Methods of treating ocular conditions |
| EP3820443A1 (en) | 2018-07-10 | 2021-05-19 | Oyster Point Pharma, Inc. | Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions |
| WO2020014217A1 (en) | 2018-07-10 | 2020-01-16 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| US20240173381A1 (en) | 2021-03-03 | 2024-05-30 | Kagoshima University | Hb-egf gene therapy for diabetes |
-
2015
- 2015-10-19 CN CN201580067940.5A patent/CN107106542B/zh active Active
- 2015-10-19 EA EA201790893A patent/EA035335B1/ru unknown
- 2015-10-19 EP EP15852340.7A patent/EP3209295B2/en active Active
- 2015-10-19 CA CA2965129A patent/CA2965129C/en active Active
- 2015-10-19 MX MX2017005064A patent/MX392383B/es unknown
- 2015-10-19 BR BR122022025737-2A patent/BR122022025737B1/pt active IP Right Grant
- 2015-10-19 PL PL20212556.3T patent/PL3848028T3/pl unknown
- 2015-10-19 US US14/887,259 patent/US9504645B2/en active Active
- 2015-10-19 US US14/887,253 patent/US9532944B2/en active Active
- 2015-10-19 PT PT158523407T patent/PT3209295T/pt unknown
- 2015-10-19 IL IL293188A patent/IL293188B2/en unknown
- 2015-10-19 US US14/887,248 patent/US9597284B2/en active Active
- 2015-10-19 KR KR1020237009057A patent/KR102601505B1/ko active Active
- 2015-10-19 DK DK15852340.7T patent/DK3209295T4/da active
- 2015-10-19 IL IL251769A patent/IL251769B/en unknown
- 2015-10-19 IL IL318427A patent/IL318427A/en unknown
- 2015-10-19 KR KR1020177013534A patent/KR102511955B1/ko active Active
- 2015-10-19 JP JP2017539528A patent/JP6873906B2/ja active Active
- 2015-10-19 SG SG10202011669PA patent/SG10202011669PA/en unknown
- 2015-10-19 DK DK20212556.3T patent/DK3848028T5/da active
- 2015-10-19 FI FIEP20212556.3T patent/FI3848028T3/fi active
- 2015-10-19 ES ES15852340T patent/ES2848977T5/es active Active
- 2015-10-19 US US14/887,243 patent/US9504644B2/en active Active
- 2015-10-19 CN CN202010304809.9A patent/CN111956650B/zh active Active
- 2015-10-19 AU AU2015336216A patent/AU2015336216B2/en active Active
- 2015-10-19 ES ES20212556T patent/ES2986830T3/es active Active
- 2015-10-19 WO PCT/US2015/056273 patent/WO2016064759A1/en not_active Ceased
- 2015-10-19 SG SG11201703135XA patent/SG11201703135XA/en unknown
- 2015-10-19 MY MYPI2017701382A patent/MY186870A/en unknown
- 2015-10-19 PT PT202125563T patent/PT3848028T/pt unknown
- 2015-10-19 CN CN202010304375.2A patent/CN111956803B/zh active Active
- 2015-10-19 EP EP24171017.7A patent/EP4413974A3/en active Pending
- 2015-10-19 BR BR112017008097-4A patent/BR112017008097B1/pt active IP Right Grant
- 2015-10-19 EP EP20212556.3A patent/EP3848028B9/en active Active
-
2017
- 2017-02-01 US US15/422,382 patent/US10456396B2/en active Active
- 2017-03-31 PH PH12017500602A patent/PH12017500602A1/en unknown
- 2017-04-19 MX MX2022005888A patent/MX2022005888A/es unknown
- 2017-05-19 ZA ZA2017/03467A patent/ZA201703467B/en unknown
-
2019
- 2019-09-10 US US16/566,237 patent/US11224598B2/en active Active
-
2020
- 2020-08-06 AU AU2020213351A patent/AU2020213351B2/en active Active
- 2020-11-20 JP JP2020193269A patent/JP7257371B2/ja active Active
-
2021
- 2021-12-06 US US17/543,505 patent/US11903941B2/en active Active
-
2022
- 2022-12-20 JP JP2022202809A patent/JP7502404B2/ja active Active
-
2023
- 2023-03-23 US US18/125,562 patent/US11903943B2/en active Active
- 2023-03-23 US US18/125,551 patent/US11911380B2/en active Active
- 2023-03-23 US US18/125,517 patent/US11903942B2/en active Active
-
2024
- 2024-01-26 US US18/423,908 patent/US20240173318A1/en not_active Abandoned
-
2025
- 2025-04-03 US US19/169,843 patent/US12576080B2/en active Active
- 2025-04-03 US US19/169,836 patent/US12653824B2/en active Active
- 2025-04-03 US US19/169,817 patent/US20250235449A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283561B (en) | Methods for treating ocular diseases | |
| IL285151B1 (en) | Methods for the treatment of fgf21-related disorders | |
| GB201701673D0 (en) | Methods of well treatment | |
| IL253244A0 (en) | Methods for treating retinal diseases | |
| IL246791A0 (en) | Compositions and methods for treating eye diseases | |
| PL3851537T3 (pl) | Leczenie hiperbilirubinemii | |
| ZA201700416B (en) | Methods for treating or preventing ophthalmological conditions | |
| IL290069A (en) | Methods for treating eye conditions | |
| ZA201706059B (en) | Method of treatment with tradipitant | |
| GB201410116D0 (en) | Method of treatment | |
| IL251769A0 (en) | Methods for treating eye conditions | |
| IL250513A0 (en) | Treatment of episode disorders | |
| IL253847A0 (en) | Methods of treating diseases | |
| IL253028B (en) | treatment method | |
| GB201416832D0 (en) | Methods of treatment | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201407806D0 (en) | Treatment of fibrosis | |
| GB201421980D0 (en) | Method of treatment | |
| GB201421982D0 (en) | Method of treatment | |
| GB201415331D0 (en) | Method of treatment | |
| GB201414780D0 (en) | Method Of Treatment | |
| HK1234660A1 (en) | Method of treating skin conditions | |
| GB201511017D0 (en) | Method of treatment | |
| AU2014905194A0 (en) | Method of Treatment |